Good morning, you're listening to Markets Desk.
Apple is heading for what analysts are calling a four hundred sixty billion dollar market cap wipeout, with shares posting their worst single-session drop following earnings in thirteen years. The culprit is guidance — management flagged supply chain pressures squeezing the outlook, and investors didn't wait around to see how it resolves.
Across the Atlantic, Novo Nordisk is dealing with its own reckoning. The Danish pharmaceutical giant saw its stock slump sharply after announcing a Phase Three clinical trial failure, a painful setback that compounds an already difficult stretch for the company. For a name that rode the weight-loss drug wave to historic heights, the reversal has been steep.
Meanwhile, inside the Federal Reserve, the dissent is getting louder. Three policymakers who pushed for a rate hike this week are making their case publicly — arguing that waiting to tighten could allow inflation to become entrenched in the broader economy. Their concern is straightforward: the longer the Fed hesitates, the harder the eventual correction becomes, for markets and for households alike.
That's the tape. Markets Desk, signing off the floor.
